JPS63218621A - 肥満症の予防・治療用組成物 - Google Patents
肥満症の予防・治療用組成物Info
- Publication number
- JPS63218621A JPS63218621A JP5387287A JP5387287A JPS63218621A JP S63218621 A JPS63218621 A JP S63218621A JP 5387287 A JP5387287 A JP 5387287A JP 5387287 A JP5387287 A JP 5387287A JP S63218621 A JPS63218621 A JP S63218621A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- obesity
- remedy
- prevention
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 13
- 208000008589 Obesity Diseases 0.000 title claims abstract description 12
- 235000020824 obesity Nutrition 0.000 title claims abstract description 12
- 230000002265 prevention Effects 0.000 title abstract 3
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 6
- -1 alkali metal salt Chemical class 0.000 claims abstract description 6
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims abstract description 6
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000000843 powder Substances 0.000 abstract description 4
- 238000007911 parenteral administration Methods 0.000 abstract description 3
- 229940024606 amino acid Drugs 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 abstract description 2
- 229960002429 proline Drugs 0.000 abstract description 2
- 159000000000 sodium salts Chemical class 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000012050 conventional carrier Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000002075 main ingredient Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- YMZJBJPWTXJQMR-LJUKVTEVSA-L Fosfomycin calcium Chemical compound [Ca+2].C[C@@H]1O[C@@H]1P([O-])([O-])=O YMZJBJPWTXJQMR-LJUKVTEVSA-L 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229960000308 fosfomycin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Landscapes
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5387287A JPS63218621A (ja) | 1987-03-09 | 1987-03-09 | 肥満症の予防・治療用組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5387287A JPS63218621A (ja) | 1987-03-09 | 1987-03-09 | 肥満症の予防・治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63218621A true JPS63218621A (ja) | 1988-09-12 |
| JPH0587048B2 JPH0587048B2 (enrdf_load_html_response) | 1993-12-15 |
Family
ID=12954841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5387287A Granted JPS63218621A (ja) | 1987-03-09 | 1987-03-09 | 肥満症の予防・治療用組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63218621A (enrdf_load_html_response) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207427B1 (en) | 1997-06-09 | 2001-03-27 | Kyowa Hakko Kogyo, Ltd. | Method for producing optically active compound |
| WO2004083179A1 (ja) * | 2003-03-19 | 2004-09-30 | Kyowa Hakko Kogyo Co., Ltd. | 糖尿病治療剤 |
| WO2004085389A1 (ja) * | 2003-03-26 | 2004-10-07 | Kyowa Hakko Kogyo Co. Ltd. | 脂質代謝改善剤 |
| WO2004087657A1 (ja) * | 2003-03-28 | 2004-10-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗肥満剤 |
| WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
| WO2006131836A3 (en) * | 2005-03-22 | 2007-10-04 | Innodia Inc | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS504066A (enrdf_load_html_response) * | 1972-11-23 | 1975-01-16 | ||
| JPS5718611A (en) * | 1980-03-05 | 1982-01-30 | Uni Maiami Za | Angiotensin converting enzyme inhibitor |
-
1987
- 1987-03-09 JP JP5387287A patent/JPS63218621A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS504066A (enrdf_load_html_response) * | 1972-11-23 | 1975-01-16 | ||
| JPS5718611A (en) * | 1980-03-05 | 1982-01-30 | Uni Maiami Za | Angiotensin converting enzyme inhibitor |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207427B1 (en) | 1997-06-09 | 2001-03-27 | Kyowa Hakko Kogyo, Ltd. | Method for producing optically active compound |
| US6365381B2 (en) | 1997-06-09 | 2002-04-02 | Kyowa Hakko Kogyo, Ltd. | Method for producing optically active compound |
| WO2004083179A1 (ja) * | 2003-03-19 | 2004-09-30 | Kyowa Hakko Kogyo Co., Ltd. | 糖尿病治療剤 |
| US7485662B2 (en) | 2003-03-19 | 2009-02-03 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for diabetes mellitus |
| WO2004085389A1 (ja) * | 2003-03-26 | 2004-10-07 | Kyowa Hakko Kogyo Co. Ltd. | 脂質代謝改善剤 |
| JPWO2004085389A1 (ja) * | 2003-03-26 | 2006-06-29 | 協和醗酵工業株式会社 | 脂質代謝改善剤 |
| WO2004087657A1 (ja) * | 2003-03-28 | 2004-10-14 | Kyowa Hakko Kogyo Co., Ltd. | 抗肥満剤 |
| JPWO2004087657A1 (ja) * | 2003-03-28 | 2006-06-29 | 協和醗酵工業株式会社 | 抗肥満剤 |
| CN100351232C (zh) * | 2003-03-28 | 2007-11-28 | 协和发酵工业株式会社 | 抗肥胖剂 |
| WO2006131836A3 (en) * | 2005-03-22 | 2007-10-04 | Innodia Inc | Compounds and compositions for use in the prevention and treatment of obesity and related syndromes |
| WO2007105730A1 (ja) * | 2006-03-13 | 2007-09-20 | Kyowa Hakko Kogyo Co., Ltd. | インスリン抵抗性改善剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0587048B2 (enrdf_load_html_response) | 1993-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2283108C2 (ru) | ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ | |
| AU2014244744B2 (en) | Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator T cells and promoting proliferation of regulator T cells | |
| JP2016028069A (ja) | 脂肪異栄養症の処置 | |
| Cevey et al. | Treatment with Fenofibrate plus a low dose of Benznidazole attenuates cardiac dysfunction in experimental Chagas disease | |
| KR101825041B1 (ko) | 물질 p를 포함하는 상처치유용 약학 조성물 | |
| TWI248359B (en) | Food materials for metabolic bone diseases | |
| JPS63218621A (ja) | 肥満症の予防・治療用組成物 | |
| JP2022166040A (ja) | 皮膚疾患の処置のためのｄｉｍの舌下又は頬側の投与 | |
| JP5048372B2 (ja) | 育毛促進剤 | |
| JP5523663B2 (ja) | 歯根−歯周組織形成促進用医薬組成物 | |
| HUE031910T2 (en) | Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals | |
| JPS60120995A (ja) | 新規アミノ酸誘導体の製法 | |
| CN117205223A (zh) | 单半乳糖基二酰基甘油半乳糖脂在制备治疗银屑病药物的应用及其药物组合物 | |
| CN117085005A (zh) | 5-羟甲基-2-呋喃甲酸在制备促血管生成相关产品中的应用 | |
| JP2021519769A (ja) | 皮膚障壁機能異常の改善用組成物 | |
| JP7364839B2 (ja) | 創傷治癒を促進する医薬品の製造におけるカンナフラビンａの使用 | |
| Zahid et al. | Effect of chloroquine on liver weight of developing albino rats | |
| CN109219451A (zh) | 包含多不饱和酮和叶酸配偶体的联合疗法 | |
| JP2004522783A (ja) | 性的機能不全を予防および治療するための医薬の製造におけるｎ−アセチル−ｄ−グルコサミンの使用 | |
| FR2605884A1 (fr) | Nouvelle association medicamenteuse | |
| EP0404660B1 (fr) | Utilisation de complexes glycoprotéines extraits de bactéries gram (-) pour la fabrication d'un médicament facilitant la cicatrisation de la peau et procédé de préparation | |
| EP3283066B1 (en) | 4-phenylbutyric acid derivatives | |
| EP0404661A2 (fr) | Utilisation de lipopolysaccharides extraits de bactéries gram (-) pour la fabrication d'un médicament facilitant la cicatrisation de la peau | |
| JP7396585B2 (ja) | Ｔｓｌｐ遺伝子発現抑制用、ｉｌ－３３遺伝子発現抑制用、又はフィラグリン産生促進用組成物 | |
| JPH02215725A (ja) | 抗高脂血症剤 |